In vitro Generation of Cytotoxic T Cells With Potential for Adoptive Tumor Immunotherapy of Multiple Myeloma

Browning, 2013, Antigen presenting cell/ tumor cell fusion vaccines for cancer immunotherapy, Hum Vaccin Immunother., 9, 1545, 10.4161/hv.24235

Koido, 2016, Dendritic-tumor fusion cell-based cancer vaccines, Int J Mol Sci., 17, 1, 10.3390/ijms17060828

Chouaib, 1988, Allogeneic T cell activation triggering by MHC class I antigens, J Immunol., 141, 423, 10.4049/jimmunol.141.2.423

Thorley-Lawson, 1985, Early events in Epstein-Barr virus infection provide a model for B cell activation, J Exp Med., 162, 45, 10.1084/jem.162.1.45

Gregory, 1988, Downregulation of cell adhesion molecules LFA-3 and ICAM-1 in Epstein-Barr virus-positive Burkitt's lymphoma underlies tumor cell escape from virus-specific T cell surveillance, J Exp Med., 167, 1811, 10.1084/jem.167.6.1811

Dunnion, 1999, Human antigen-presenting cell-tumour cell hybrids stimulate strong allogeneic responses and present tumour-associated antigens to cytotoxic T cells in vitro, Immunology., 98, 541, 10.1046/j.1365-2567.1999.00912.x

Cywinski, 2006, Hybrid cells formed by fusion of Epstein-Barr virus-associated B-lymphoblastoid cells and either marrow-derived or solid tumour-derived cell lines display different co-stimulatory phenotypes and abilities to activate allogeneic T-cell responses in vitro, Tissue Antigens., 68, 115, 10.1111/j.1399-0039.2006.00623.x

Walewska, 2007, Preclinical development of hybrid cell vaccines for multiple myeloma, Euro J Haematol., 78, 11, 10.1111/j.1600-0609.2006.00769.x

Edwards, 1982, A human-human hybridoma system based on a fast-growing mutant of the ARH-77 plasma cell leukemia-derived line, Euro J Immunol., 12, 641, 10.1002/eji.1830120804

Mohamed, 2012, In vitro evaluation of human hybrid cell lines generated by fusion of B-lymphoblastoid cells and ex vivo tumour cells as candidate vaccines for haematological malignancies, Vaccine., 30, 6578, 10.1016/j.vaccine.2012.08.032

Mohamed, 2012, Long-lived fusions of human haematological tumour cells and B-lymphoblastoid cells induce tumour antigen-specific cytotoxic T-cell responses in vitro, Immunobiology., 217, 719, 10.1016/j.imbio.2011.12.001

Hosken, 1990, Defective presentation of endogenous antigen by a cell line expressing class I molecules, Science, 248, 367, 10.1126/science.2326647

Nishimura, 1994, Protection against natural killer cells by interferon-gamma treatment of K562 cells cannot be explained by augmented major histocompatibility complex class I expression, Immunology., 83, 75

Perica, 2015, Adoptive T cell immunotherapy for cancer, Rambam Maimonides Med J., 6, e0004, 10.5041/RMMJ.10179

Chung, 2017, Role of immunotherapy in tergeting the bone marrow microenvironment in multiple myeloma:an evolving therapeutic strategy, Pharmacotherapy., 37, 129, 10.1002/phar.1871

Pratt, 2007, Immunodeficiency and immunotherapy in multiple myeloma, Br J Haematol., 138, 563, 10.1111/j.1365-2141.2007.06705.x

Witzens-Harig, 2013, Tumor cells in multiple myeloma patients inhibit myeloma-reactive T cells through carcinoembryonic antigen-related cell adhesion molecule-6, Blood., 121, 4493, 10.1182/blood-2012-05-429415

Dhodapkar, 2002, T cells from the tumor microenvironment of patients with progressive myeloma can generate strong, tumor-specific cytolytic responses to autologous, tumor-loaded dendritic cells, Proc Natl Acad Sci USA., 99, 13009, 10.1073/pnas.202491499

Hayashi, 2003, Ex vivo induction of multiple myeloma-specific cytotoxic T lymphocytes, Blood., 102, 1435, 10.1182/blood-2002-09-2828

Rosenblatt, 2013, Vaccination with dendritic cell/tumor fusions following autologous stem cell transplant induces immunologic and clinical responses in multiple myeloma patients, Clin Cancer Res., 19, 3640, 10.1158/1078-0432.CCR-13-0282

Raje, 2004, Tumour cell/dendritic cell fusions as a vaccination strategy for multiple myeloma, Br J Haematol., 125, 343, 10.1111/j.1365-2141.2004.04929.x

Rapoport, 2005, Restoration of immunity in lymphopenic individuals with cancer by vaccination and adoptive T-cell transfer, Nat Med., 11, 1230, 10.1038/nm1310

Rapoport, 2011, Combination immunotherapy using adoptive T-cell transfer and tumor antigen vaccination on the basis of hTERT and survivin after ASCT for myeloma, Blood., 117, 788, 10.1182/blood-2010-08-299396

Rosenblatt, 2010, Generation of tumor-specific T lymphocytes using dendritic cell/tumor fusions and anti-CD3/CD28, J Immunother., 33, 155, 10.1097/CJI.0b013e3181bed253

Bruno, 2009, Role of allogeneic stem cell transplantation in multiple myeloma, Semin Hematol, 46, 158, 10.1053/j.seminhematol.2009.02.001

Van De Donk, 2006, Prognostic factors for donor lymphocyte infusions following non-myeloablative allogeneic stem cell transplantation in multiple myeloma, Bone Marrow Transplant., 37, 1135, 10.1038/sj.bmt.1705393

Levenga, 2007, Multiple myeloma patients receiving pre-emptive donor lymphocyte infusion after partial T-cell-depleted allogeneic stem cell transplantation show a long progression-free survival, Bone Marrow Transplant., 40, 355, 10.1038/sj.bmt.1705742

Kroger, 2009, Post-transplant immunotherapy with donor-lymphocyte infusion and novel agents to upgrade partial into complete and molecular remission in allografted patients with multiple myeloma, Exp Hematol., 37, 791, 10.1016/j.exphem.2009.03.008

Vallet, 2017, Adoptive cell therapy in multiple myeloma, Exp Opin Biol Ther, 17, 1511, 10.1080/14712598.2017.1375095

Cloosen, 2006, Cancer specific Mucin-1 glycoforms are expressed on multiple myeloma, Br J Haematol., 135, 513, 10.1111/j.1365-2141.2006.06331.x

Meklat, 2007, Cancer-testis antigens in haematological malignancies, Br J Haematol., 136, 769, 10.1111/j.1365-2141.2006.06484.x

Schmitt, 2008, RHAMM-R3 peptide vaccination in patients with acute myeloid leukemia, myelodysplastic syndrome, and multiple myeloma elicits immunologic and clinical responses, Blood., 111, 1357, 10.1182/blood-2007-07-099366

De Carvalho, 2012, Cancer/testis antigen MAGE-C1/CT7: new target for multiple myeloma therapy, Clin Dev Immunol., 2012, 257695, 10.1155/2012/257695

Tai, 2008, Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu, Blood., 112, 1329, 10.1182/blood-2007-08-107292

Yin, 2012, Inhibition of the MUC1-C oncoprotein induces multiple myeloma celldeath by down-regulating TIGAR expression and depleting NADPH, Blood., 119, 810, 10.1182/blood-2011-07-369686

Tai, 2009, CS1 promotes multiple myeloma cell adhesion, clonogenic growth, and tumorigenicity via c-maf–mediated interactions with bone marrow stromal cells, Blood., 113, 4309, 10.1182/blood-2008-10-183772

Brossart, 1999, Identification of HLA-A2–restricted T-cell epitopes derived from the MUC1 tumor antigen for broadly applicable vaccine therapies, Blood., 93, 4309, 10.1182/blood.V93.12.4309

Minev, 2000, Cytotoxic T cell immunity against telomerase reverse transcriptase in humans, Proc Natl Acad Sci USA, 97, 4796, 10.1073/pnas.070560797

Lendvai, 2010, Cellular immune responses against CT7 (MAGE-C1) and humoral responses against other cancer-testis antigens in multiple myeloma patients, Cancer Immun., 10, 4

Kim, 2013, CS1 (SLAMF7) inhibits production of proinflammatory cytokines by activated monocytes, Inflamm Res., 62, 765, 10.1007/s00011-013-0632-1

Spaapen, 2010, Eradication of medullary multiple myeloma by CD4+ cytotoxic human T lymphocytes directed at a single minor histocompatibility antigen, Clin Cancer Res., 16, 5481, 10.1158/1078-0432.CCR-10-1340

Mimura, 2011, T cell recognition of HLA-A2 restricted tumor antigens is impaired by the oncogene HER2, Int J Cancer., 128, 390, 10.1002/ijc.25613

Komlos, 1995, Contribution of class I HLA-A2 antigen in immune reactions, Med Hypotheses., 45, 54, 10.1016/0306-9877(95)90203-1

Browning, 1996, Genetic diversity of HLA-A2: evolutionary and functional significance, Immunol Today, 17, 165, 10.1016/0167-5699(96)80614-1

Khalaf, 2017, In vitro Generation of cytotoxic T cells with potential for adoptive tumour immunotherapy